Shares of Liberty Biopharma Inc (CVE:LTY – Get Free Report) were up ∞ during trading on Tuesday. The stock traded as high as C$2.00 and last traded at C$2.00. 700 shares were traded during trading, a decline of 97% from the average daily volume of 23,286 shares.
Liberty Biopharma Stock Performance
The stock has a market cap of C$21.54 million and a price-to-earnings ratio of -12.66. The company’s 50-day simple moving average is C$2.00 and its 200-day simple moving average is C$2.00. The company has a quick ratio of 0.12, a current ratio of 0.12 and a debt-to-equity ratio of 8.19.
Liberty Biopharma Company Profile
Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease.
Recommended Stories
- Five stocks we like better than Liberty Biopharma
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Liberty Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liberty Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
